| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/31/2002 | CN1361774A Heterocyclic substituted aminoazacycles useful as central nervous system agents |
| 07/31/2002 | CN1361773A Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/31/2002 | CN1361768A Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| 07/31/2002 | CN1361767A 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 07/31/2002 | CN1361766A Tricyclic compounds bearing acyloxymethoxy-carbonyl pendants |
| 07/31/2002 | CN1361765A Inhibitors of aspartyl protease |
| 07/31/2002 | CN1361763A Aminobenzophenones as inhibitors of IL-1 beta and TNF_alpha |
| 07/31/2002 | CN1361760A Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators |
| 07/31/2002 | CN1361698A Prolyl endopeptidase inhibitor |
| 07/31/2002 | CN1361697A Use of ginkgo extract |
| 07/31/2002 | CN1361693A Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance |
| 07/31/2002 | CN1361692A Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts |
| 07/31/2002 | CN1361691A New use of a macrolide compound |
| 07/31/2002 | CN1361690A Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 07/31/2002 | CN1361689A Stable xylometazoline and oxymetazoline solution |
| 07/31/2002 | CN1361688A Nitroimidazole external preparations for dermatosis |
| 07/31/2002 | CN1361687A Phosphate transport inhibitors |
| 07/31/2002 | CN1361684A Biodegradable poly (alkylene oxide)-poly cp-dioxanone) block copolymer soluble in organic solvents, and drug delivery composition comprising same |
| 07/31/2002 | CN1361683A Novel preparation and administration form comprising an acid-labile active compound |
| 07/31/2002 | CN1361681A Methods for preparation of lipid-encapsulated therapeutic agents |
| 07/31/2002 | CN1361677A Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 07/31/2002 | CN1361236A Transesterification products of corn oil and glycerol and its producing process |
| 07/31/2002 | CN1361111A Furost saponine analogue and its separation process and use |
| 07/31/2002 | CN1360934A Nanometer Baofukang medicine for women's health and its prepn |
| 07/31/2002 | CN1360908A Chinese traditional medicine prepn for preventing and/or treating irritable myocardial injury |
| 07/31/2002 | CN1360905A Cancer treating astringent medicine decoction |
| 07/31/2002 | CN1360901A Snuff xinnaokang for treating cardiovascular and cerebrovascular disease |
| 07/31/2002 | CN1360896A Medicine for treating cervical vertebra disease |
| 07/31/2002 | CN1360895A Medical composition for treating dermatosis |
| 07/31/2002 | CN1360894A Epimedium polysaccharide and its application in preparing medicine for raising body's immunity |
| 07/31/2002 | CN1360893A Sobering-up liver-protecting compound prepn |
| 07/31/2002 | CN1360892A Dry mixed suspension of Meptin and pseudoephe and its prepn |
| 07/31/2002 | CN1360891A Dithiolane amylene hepyrroleketone and its relative monoxide and dioxide using as antitumour agent |
| 07/31/2002 | CN1360890A Use of active retiene derivative with negative hormone and/or antagonist |
| 07/31/2002 | CN1360889A Externally applied medicine for women's wedding night |
| 07/31/2002 | CN1360888A Mixed antigen medicine for treating benign and malignant skin lesion |
| 07/31/2002 | CN1088460C Process for isolating galanthamine |
| 07/31/2002 | CN1088459C 1,4-disubstituted piperazines |
| 07/31/2002 | CN1088456C Substituted oxazolidine calpain and/or cathepsin B inhibitors |
| 07/31/2002 | CN1088379C 三七软胶囊 Thirty-seven soft capsules |
| 07/31/2002 | CN1088376C Compound hemostatic |
| 07/31/2002 | CN1088369C Moxibustion liquid and its producing method |
| 07/31/2002 | CN1088364C Traditional Chinese medicine composition for treating ischemic encephalopathy and preparation process thereof |
| 07/31/2002 | CN1088362C Method of administering azithromycin |
| 07/31/2002 | CN1088361C Combined use of diclofenac and tribenoside to treat osteoarthritis |
| 07/31/2002 | CN1088360C High efficient anti-inflammatory and antipruritic ointment and its producing method |
| 07/31/2002 | CN1088359C Medicine for curing cerebrovascular disturbance with psychonosema |
| 07/31/2002 | CN1088358C Antitussive composition containing antitussive and benzydamine |
| 07/31/2002 | CN1088357C Microgranules of 5-nitro imidazole derivatives |
| 07/31/2002 | CA2369462A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of pde4 isozymes |
| 07/30/2002 | US6426422 Method for the preparation of citalopram |
| 07/30/2002 | US6426417 Processes and intermediates useful to make antifolates |
| 07/30/2002 | US6426413 Inhibitors of caspases |
| 07/30/2002 | US6426409 Nucleic acid molecules that bind prion proteins and processes for the production thereof |
| 07/30/2002 | US6426405 Therapeutic target for treatment of diseases associated with altered muscle activity of pain transmission; has properties of glycine transporter associated with strychnine sensitive glycine receptors--properties called ?sc6? activity |
| 07/30/2002 | US6426369 Oxethazaine as antimicrobial agent |
| 07/30/2002 | US6426368 Method for preventing and treating alcoholism |
| 07/30/2002 | US6426367 Methods for selectively occluding blood supplies to neoplasias |
| 07/30/2002 | US6426366 Pharmaceutical compositions comprising tyrphostins |
| 07/30/2002 | US6426365 CETP activity inhibitors |
| 07/30/2002 | US6426363 Mixture containing triglyceride, surfactants |
| 07/30/2002 | US6426362 Formulations of tocopherols and methods of making and using them |
| 07/30/2002 | US6426361 Method and compositions for increasing the anaerobic working capacity in tissues |
| 07/30/2002 | US6426359 Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists |
| 07/30/2002 | US6426358 Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
| 07/30/2002 | US6426357 Antagonists of follicle stimulating hormone activity |
| 07/30/2002 | US6426356 Analgesics; hypotensive agents; antidepressants |
| 07/30/2002 | US6426355 Viricides; prevention production |
| 07/30/2002 | US6426354 Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme |
| 07/30/2002 | US6426353 α v integrin receptor antagonists |
| 07/30/2002 | US6426350 Alpha-2 adrenoceptor antagonists; use treating nervous system disorders |
| 07/30/2002 | US6426349 Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes for neoplasia |
| 07/30/2002 | US6426348 For therapy of inflammation associated with chronic inflammatory diseases such as rheumatoid arthritis (ra), multiple sclerosis, (ms), asthma, and inflammatory bowel disease (i bd) |
| 07/30/2002 | US6426347 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands |
| 07/30/2002 | US6426345 Phosphodiesterase inhibitors; antiinflammatory agents |
| 07/30/2002 | US6426344 Aryl and heteroaryl substituted indolealkanoic acids |
| 07/30/2002 | US6426343 Preparation and use of a specific GABA-Aα5 receptor ligand for treatment of Alzheimer's disease |
| 07/30/2002 | US6426342 Clavulanic acid, salts or esters along with a carrier for controlled release |
| 07/30/2002 | US6426341 Treatment for diabetic complications |
| 07/30/2002 | US6426340 Complex with glycine or taurine |
| 07/30/2002 | US6426339 In situ; sustained release; preadministering glucocorticosteroid |
| 07/30/2002 | US6426338 Therapy for constipation |
| 07/30/2002 | US6426337 Antiinflammatory agents |
| 07/30/2002 | US6426335 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| 07/30/2002 | US6426334 Administering nucleotide sequence |
| 07/30/2002 | US6426201 Mixing cereal with water; freezing |
| 07/30/2002 | US6426199 Isolated, purified nucleic acid detecting or isolating mutant forms of the dna molecules. |
| 07/30/2002 | US6426100 Method for improving bone modeling and chondrocyte functioning in growing canines |
| 07/30/2002 | US6426097 Herbal supplement for cognitive related impairment due to estrogen loss |
| 07/30/2002 | US6426096 Adminstering chromium compound |
| 07/30/2002 | US6426094 Method of enhancing the efficacy of anti-tumor agents |
| 07/30/2002 | US6426092 Powder compositions comprising a skin irritation reducing agent |
| 07/30/2002 | US6426091 Sustained-release theophylline tablet |
| 07/30/2002 | US6426087 Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent |
| 07/30/2002 | US6426085 Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| 07/30/2002 | US6426084 Treatment of sexual dysfunction in certain patient groups |
| 07/30/2002 | US6426076 Ascorbic acid as an adjuvant in the treatment of malignant tumors using chemotherapy and radiotherapy |
| 07/30/2002 | US6426069 Method and compositions for increasing intestinal absorption of fats |
| 07/30/2002 | US6426067 Cardiovascular disorders; antitumor agents |
| 07/30/2002 | US6425892 Device for transdermal electrotransport delivery of fentanyl and sufentanil |